BRUSSELS, BELGIUM -- 07/31/09 --
* Multiple launches: Cimzia®/RA in the U.S., Vimpat®/epilepsy in
the U.S. and in the EU, Neupro®/new patients Parkinson's disease
and Neupro®/RLS in the EU
* Total revenue decreased as expected by 6% to EUR 1.6 billion: net
sales declined by 10% to EUR 1.4 billion as a consequence of
generic competition to Keppra® in the U.S., partially compensated
by the strong performance of Keppra® in Europe and the new
product launches of Vimpat® and Cimzia®. Royalty income increased
by 35% to EUR 114 million supported by the launch of Toviaz®.
Other revenue increased by 44% to EUR 103 million due to the good
performance of Xyzal® in the U.S. and higher contract
manufacturing sales
* Underlying profitability (recurring EBITDA) increased by 1% to
EUR 363 million reflecting generic competition more than
compensated by significantly lower operating expenses as a result
of SHAPE
* Reported net profit after minorities almost quadrupled to EUR 516
million from EUR 108 million in 2008, of which EUR 455 million
attributed to capital gains on divestitures
* Phase II trials for CDP7851 in fracture healing and
postmenopausal osteoporosis (PMO) initiated
* Outlook 2009 confirmed: Full year total revenue expected to reach
between EUR 3.1 - 3.3 billion; underlying profitability
(recurring EBITDA) expected to end the year greater than EUR 680
million; net profit as reported increased to EUR 550 million
Brussels (Belgium), 31 July 2009 - 7:00 AM (CET) - press release,
regulated information - UCB announced today its consolidated half
year 2009 financial results. The first half year of 2009 is marked by
progress with clinical development, operational and financial
performance, and by a record number of product launches.
"Our Half-Year Report 2009 records significant progress for UCB. With
multiple product launches underway showing already promise, we at UCB
now have the future in our hands," said Roch Doliveux, Chief
Executive Officer, UCB. "We are focusing on the successful
commercialization of our major new products Cimzia®, Vimpat® and
Neupro® in order to bring benefit to patients living with severe
disease. At the same time, we are striving for improved efficiency
and more partnerships to strengthen our performance and to continue
transforming UCB into the next generation biopharma leader."
The full press release can be downloaded from the following link:
Half-Year Report 2009: http://hugin.info/133973/R/1331890/315348.pdf
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
For further information
Richard Simpson
Investor Relations, UCB
T+32.2.559.949
Email Contact
Michael Tuck-Sherman
Investor Relations, UCB
T +32.2.559.9712
Email Contact
Nancy Nackaerts
External Communications, UCB
T +32.2.559.9264
Email Contact
